Sandoz plans to open a new Biosimilar Technical Development Centre with an investment of US$90 million.
The new state-of-the-art end-to-end drug product development centre represents a significant investment in biopharma technical development capabilities.
This facility will likely focus on the production of biologic medicines, further enhancing the biopharmaceutical industry.
The centre will focus on biosimilar product development and will become one of the key locations for this type of work.
This new development centre is part of a larger expansion effort in the biopharmaceutical sector.
Moreover, it also expands its biosimilar development capabilities at its facility in Holzkirchen, Germany, which indicates a strong commitment to the growth and advancement of biosimilar therapies.
The new Biosimilar Development Centre will meet the rapidly growing demand for biosimilars, contributing significantly to the long-term sustainability of healthcare systems worldwide.
This investment will lead to the creation of approximately 200 new full-time jobs and establish a dedicated Biopharma Development Centre by 2026.
Type New Construction
Budget US$90 million